Double attack on melanoma: trial tests powerful drug combo before surgery
NCT ID NCT04139902
Summary
This study compares two immunotherapy approaches given before surgery for advanced melanoma that can still be removed. Patients receive either one immunotherapy drug or a combination of two drugs for 6 weeks before their operation, followed by additional treatment afterward. The goal is to see which approach better shrinks the cancer before surgery and improves long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UPMC Hillman Cancer Center Washington
Washington, Pennsylvania, 15301, United States
Conditions
Explore the condition pages connected to this study.